Weighing HER2 vs IDH2 targets in cholangiocarcinoma

Dr Haley Ellis from Mass General Brigham Cancer Institute in Boston, Massachusetts, Prof Eric Van Cutsem from University Hospitals Leuven in Belgium, Dr Zev Wainberg from UCLA Jonsson Comprehensive Cancer Center in Los Angeles, California, and moderator Dr Lionel A Kankeu Fonkoua from Mayo Clinic in Rochester, Minnesota, discuss recent data and provide their perspectives on the management of HER2-positive GI cancers.

CME information and select publications here.